Article Details
Retrieved on: 2025-09-01 17:29:32
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... monoclonal antibodies, which account for more than 75% of bioprocessing revenues. However, DHR stock has performed weaker than its rival, IDEXX ...
Article found on: www.newsbreak.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here